AML Hub

AML Hub

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Episoder(33)

Know AML webinar | Closing remarks and Q&A

Know AML webinar | Closing remarks and Q&A

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the...

26 Jun 20259min

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hoste...

19 Jun 20259min

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz...

13 Jun 202527min

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charl...

9 Jun 202513min

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission p...

3 Okt 20245min

CPX-351 as first-line treatment in AML: Real-world data

CPX-351 as first-line treatment in AML: Real-world data

Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy fo...

30 Sep 202416min

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consens...

17 Sep 202413min

What were your highlights from ASH 2023?

What were your highlights from ASH 2023?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. Se...

29 Apr 20243min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
treningspodden
foreldreradet
merry-quizmas
dopet
jakt-og-fiskepodden
rss-sunn-okonomi
podme-bio-3
rss-strid-de-norske-borgerkrigene
hverdagspsyken
sovnlos
rss-kull
sinnsyn
gravid-uke-for-uke
tomprat-med-gunnar-tjomlid
rss-var-forste-kaffe
dypdykk
fryktlos